Seres Therapeutics (MCRB) analyst forecast and price target
Analyst forecast
Consensus of 2 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Initiated Coverage | Buy | $12.00 | Jun 23, 2026 |
| Canaccord Genuity | Maintained | Buy | $22.00 | Mar 13, 2026 |
| Canaccord Genuity | Maintained | Buy | $22.00 from $14.00 | Sep 24, 2025 |
| Chardan Capital | Downgraded | Buy → Neutral | $6.00 from $1.25 | May 8, 2025 |
| Chardan Capital | Maintained | Buy | $1.25 | Mar 20, 2025 |
| Goldman Sachs | Maintained | Sell | $0.75 from $1.00 | Mar 14, 2025 |
| Canaccord Genuity | Maintained | Buy | $10.00 | Nov 14, 2024 |
| Chardan Capital | Maintained | Buy | $1.25 | Nov 13, 2024 |
| JP Morgan | Downgraded | Neutral → Underweight | — | Oct 24, 2024 |
| Canaccord Genuity | Maintained | Buy | $10.00 | Sep 13, 2024 |
| Chardan Capital | Maintained | Buy | $1.25 | Aug 14, 2024 |
| Canaccord Genuity | Maintained | Buy | $10.00 | Aug 14, 2024 |
| Canaccord Genuity | Maintained | Buy | $10.00 from $15.00 | Jun 7, 2024 |
| Oppenheimer | Downgraded | Outperform → Perform | — | Jun 7, 2024 |
| Oppenheimer | Maintained | Outperform | $4.00 from $5.00 | May 9, 2024 |
| Chardan Capital | Maintained | Buy | $6.00 from $8.00 | May 8, 2024 |
| Chardan Capital | Maintained | Buy | $8.00 from $10.00 | Mar 6, 2024 |
| Oppenheimer | Maintained | Outperform | $5.00 from $9.00 | Mar 6, 2024 |
| Oppenheimer | Maintained | Outperform | $9.00 from $10.00 | Jan 16, 2024 |
| Goldman Sachs | Maintained | Sell | $1.25 from $4.00 | Nov 3, 2023 |
Frequently asked questions
Is MCRB a buy, sell, or hold?
Analysts covering Seres Therapeutics currently average a Buy rating: 2 buy, 0 hold and 0 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on MCRB?
On Jun 23, 2026, HC Wainwright & Co. initiated coverage of Seres Therapeutics at Buy with a price target of $12.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.